Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma.

Shukla R, Upton KR, Muñoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, Dos Santos A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccarelli FD, Garcia-Perez JL, Faivre J, Faulkner GJ. · 2013

Read Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. by Shukla R, Upton KR, Muñoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, Dos Santos A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccarelli FD, Garcia-Perez JL, Faivre J, Faulkner GJ. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3898742.txt.

Introduction

Ruchi Shukla leads a large team in a liver cancer study in Cell in 2013. LINE-1 elements are jumping DNA that makes up a large share of the human genome. New jumps can break genes and cause disease, but their role in cancer was unclear. The team hunt them in liver tumors.

A tuned capture method read jump sites across a set of liver cancer genomes. Two clear cancer paths emerged. In several donors, an inherited jump had silenced a tumor suppressor gene, freeing a growth pathway. In another case, a tumor-only jump switched on a gene by blocking its off switch, and lab tests confirmed the mechanism. That gene was also often extra-copied in mouse liver tumors. Jumping DNA joins the list of liver cancer causes.

Catalog record

CREATORShukla R, Upton KR, Muñoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, Dos Santos A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccarelli FD, Garcia-Perez JL, Faivre J, Faulkner GJ.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3898742

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Endogenous Retrotransposition Activates Oncogenic Pathways in Hepatocellular Carcinoma By Ruchi Shukla, Kyle R Upton, Martin Muñoz-Lopez, Daniel J Gerhardt, Malcolm E Fisher, Thu Nguyen, Paul M Brennan, J Kenneth Baillie, Agnese Collino, Serena Ghisletti, Shruti Sinha, Fabio Iannelli Published in: Cell DOI: 10.1016/j.cell.2013.02.032 ABSTRACT Summary LINE-1 (L1) retrotransposons are mobile genetic elements comprising ∼17% of the human genome. New L1 insertions can profoundly alter gene function and cause disease, though their significance in cancer remains unclear. Here, we applied enhanced retrotransposon capture sequencing (RC-seq) to 19 hepatocellular carcinoma (HCC) genomes and elucidated two archetypal L1-mediated mechanisms enabling tumorigenesis. In the first example, 4/19 (21.1%) donors presented germline retrotransposition events in the tumor suppressor mutated in colorectal cancers (MCC). MCC expression was ablated in each case, enabling oncogenic β-catenin/Wnt signaling. In the second example, suppression of tumorigenicity 18 (ST18) was activated by a tumor-specific L1 insertion. Experimental assays confirmed that the L1 interrupted a negative feedback loop by blocking ST18 repression of its enhancer. ST18 was also frequently amplified in HCC nodules from Mdr2−/− mice, supporting its assignment as a candidate liver oncogene. These proof-of-principle results substantiate L1-mediated retrotransposition as an important etiological factor in HCC. INTRODUCTION Liver cancer accounts for 9% of all cancer deaths worldwide and 12% in developing countries (Jemal et al., 2011). Pathological inspection indicates hepatocellular carcinoma (HCC) in ∼80% of liver tumors, with infection by hepatitis B virus (HBV) and hepatitis C virus (HCV) being the most prevalent risk factors, followed by chronic alcoholism (Jemal et al., 2011; Perz et al., 2006; Tateishi and Omata, 2012). Although early detection and monitoring of patients with liver cirrhosis can substantially improve 5 year survival rates, progression to advanced HCC reduces average life expectancy to less than 8 months (Llovet et al., 2008). As for other cancers, genome and exome resequencing have elucidated molecular pathways frequently perturbed in HCC (Guichard et al., 2012; Tateishi and Omata, 2012; Totoki et al., 2011), potentially enabling therapeutic intervention informed by the mutational signature of a given tumor. The capacity to catalog the full spectrum of genetic aberrations occurring in HCC is therefore of critical importance. LINE-1 (L1) retrotransposons are a major source of endogenous mutagenesis in humans (Burns and Boeke, 2012; Levin and Moran, 2011). These mobile genetic elements utilize a “copy-and-paste” mechanism to retrotranspose to new genomic loci, with such success in germ cells that 500,000 L1 copies comprise ∼17% of the genome (Lander et al., 2001). Of these copies, only 80–100 are transposition competent, with distinct subsets of frequently active—or “hot”—L1s driving insertional mutagenesis in each individual genome (Beck et al., 2010; Brouha et al., 2003). Retrotransposon insertions can profoundly alter gene structure and expression (Cordaux and Batzer, 2009; Faulkner et al., 2009; Han et al., 2004; Levin and Moran, 2011) and have been found in nearly 100 cases of disease (Faulkner, 2011; Hancks and Kazazian, 2012). L1 activity is consequently suppressed in most somatic cells by methylation of a CpG island in the internal L1 promoter (Coufal et al., 2009; Swergold, 1990). By contrast, L1 is often hypomethylated in tumor cells, removing a key obstacle to retrotransposition (Levin and Moran, 2011). Despite this failure to repress L1 transcription, only a handful of L1 insertions had been found in human tumors until very recently (Liu et al., 1997; Miki et al., 1992). High-throughput L1 integration site sequencing has since revealed 9 and 69 de novo L1 insertions, respectively, in lung and colorectal tumors (Iskow et al., 2010; Solyom et al., 2012), whereas cancer genome resequencing elucidated a further 183 tumor-specific L1 insertions in colorectal, ovarian, and prostate cancer (Lee et al., 2012). In this latter study, more than half of all insertions were found in a single colorectal tumor; the other individuals presented fewer than five tumor-specific L1 insertions on average. These data suggest L1 mobilization may be common in epithelial tumors, though the reasons for possible cell-of-origin restriction are currently unknown. Tumor-specific L1 retrotransposition has not previously been observed in HCC. For several reasons it is, however, a logical cancer in which to expect L1 mobilization. First, HCC is epithelial in origin. Second, HBV and HCV infection are common in HCC; viruses can suppress host defense factors, such as APOBEC proteins, that control retrotransposon activation. APOBEC3G has been shown, for instance, to inhibit both HBV replication and endogenous retrotransposition (Esnault et al., 2005; Turelli et al., 2004). Third, liver inflammation precedes HCC and may, via cellular stress, stimulate retrotransposition (Fornace and Mitchell, 1986). Given these facts, we aimed to map L1 integration sites in HCC using retrotransposon capture sequencing (RC-seq) and assess their impact upon oncogenic and tumor suppressor pathways. RESULTS Enhanced Retrotransposon Capture Sequencing To test the hypothesis that L1 mobilizes in HCC, we applied an updated RC-seq protocol to 19 HCC tumors and matched adjacent liver tissue that were confirmed positive for HBV or HCV infection (Table 1). An earlier RC-seq design (Baillie et al., 2011) was modified to incorporate multiplex liquid-phase sequence capture (Figure 1A) using a refined probe pool (Table S1 available online) and a reduced insert size of ∼220 nt, which enabled high-confidence assembly of overlapping paired-end 150 nt reads (Figure 1B). This change simplified genomic alignment and, more importantly, enabled single-nucleotide resolution of retrotransposon integration sites (Figure 1C). [Table: Nonreference Genome Insertions Detected by RC-Seq] [Figure: Enhanced RC-Seq(A) Multiplexed Illumina libraries are hybridized to liquid-phase sequence capture probes targeting the 5′ and 3′ ends of recently active human retrotransposons (Table S1).(B) Paired-end 150-mer sequencing of ∼220 nt inserts enables “contig” assembly of each read pair into a single read.(C) Assembled reads with a 5′ or 3′ section of an active retrotransposon at one end (highlighted in red) are retained. The opposite end is then aligned to the reference genome, indicating the position of known and novel insertions.] After stringent filtering and mapping, an average of ∼2 million reads were retained per library with >95% identity to active L1, Alu, and SVA families, as well as the most recently active human LTR endogenous retroviruses (Table S2). Optimized sequence capture led to a 4-fold increase in reads aligned to nonreference genome L1s per library compared to previous RC-seq based on solid-phase arrays and similar sequencing depth (Baillie et al., 2011). The improved resolution of RC-seq also allowed us to discriminate a required minimum of two unique amplicons in support of any nonreference genome insertion (see Extended Experimental Procedures). Extended Experimental ProceduresSample PreparationSnap frozen HCC tissue samples were obtained from 19 patients who underwent surgery at the Centre Hépatobiliaire, Paul-Brousse Hospital (Table 1). The study was reviewed and approved by the Institutional Review Board (IRB) of the French Institute of Medical Research and Health INSERM (IRB Number 11-047). Specimens were obtained after surgical resection or from liver explants at transplantation. For each patient, we analyzed tumor and distal nontumor tissue (T/NT pairs). Ten patients presented HBV-induced cirrhoses, confirmed by initial pathology and by detection of HBV-surface antigen and HBx protein (see the Extended Experimental Procedures). HCV infection was confirmed for nine patients by enzyme-linked immunosorbent assay (Monolisa HCV Ag-Ab; BIO-RAD) according to the manufacturer’s instructions. Total DNA was isolated using the DNeasy blood & tissue kit (QIAGEN). Total RNA was extracted using the mirVana miRNA isolation

Read the complete text